Pharmaceutical

Cidara to continue its CD388 influenza programme despite Janssen’s contrary decision

Janssen has plans to discontinue the CD388 influenza programme as part of pipeline prioritisation, but Cidara plans to continue development.

Jul 21, 2023 - 20:00
Cidara to continue its CD388 influenza programme despite Janssen’s contrary decision
Janssen has plans to discontinue the CD388 influenza programme as part of pipeline prioritisation, but Cidara plans to continue development.
Read the original article

Tags:

Previous Article

Idorsia sells off its Asia Pacific operations to raise funds

Next Article

Controlling the pharma machine: EMA conveys thoughts on AI use in industry

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma

Health Canada issues NOC to J&J’s CARVYKTI for multiple...

Nov 23, 2024

STAT+: Morphic study shows promise — and blockbuster potential — for a pill to treat ulcerative colitis

STAT+: Morphic study shows promise — and blockbuster po...

Apr 25, 2023

AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership

AstraZeneca picks first Treg cell therapy from Quell Th...

Nov 19, 2024